| Preview
Full Doc
 | 2003 |
Heritage Property Investment Trust, Inc. Announces Exercise of Over-Allotment Option
Heritage Property Investment Trust, Inc. Announces Exercise of Over-Allotment Option (4K)
Doc #267562: Click preview link for longer preview.
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION
BOSTON, December 26, 2003 /PRNewswire-FirstCall/ Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced that Deutsche Bank Securities Inc., the underwriter for its recently completed equity offering, has exercised its over-allotment option and has purchased an additional 672,045 shares of our common stock. As a result, Heritage has sold an additional 432,736 shares and The Prudential Insurance Company of America, our second largest stockholder, has sold an additional 239,309 shares. The sale of these additional shares is expected to close on December 30, 2003.
Heritages largest stockholder, Net Realty Holding Trust, a subsidiary of The New England Teamsters and Trucking Industry Pension Fund, has agreed to purchase 172,045 shares, or approximately 40% of these additional shares being offered by Heritage, pursuant to a contractual right Heritage granted to Net Realty Holding Trust to permit it to maintain its ownership percentage in the Company. Net Realty Holding Trust will purchase these additional shares on the same terms and conditions as other purchasers.
The net proceeds to Heritage from the sale of these additional shares, after deducting estimated offering expenses, will be approximately $12 million. Heritage intends to use the net proceeds of the offering to repay indebtedness.
267562
|
Deutsche Bank
As referenced in this Heritage Property Investment Trust, Inc. Announces Exercise of Over-Allotment Option:
Deutsche Bank Securities Inc – INC. ANNOUNCES
EXERCISE OF OVER-ALLOTMENT OPTION
BOSTON, December 26, 2003 /PRNewswire-FirstCall/ Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced that Deutsche Bank Securities Inc ., the underwriter for its recently completed equity offering, has exercised its over-allotment option and has purchased an additional 672,045 shares _____________
dt 161597
;
Heritage
As referenced in this Heritage Property Investment Trust, Inc. Announces Exercise of Over-Allotment Option:
HERITAGE PROPERTY INVESTMENT TRUST, – President, Finance and Accounting
(Analyst Info)
(General Info)
(617) 247-2200
(312) 640-6745
(212) 445-8434
posullivan@heritagerealty.com
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. ANNOUNCES
EXERCISE OF OVER-ALLOTMENT OPTION
BOSTON, December 26, 2003 /PRNewswire-FirstCall/ Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced _____________
Heritage Property Investment Trust, – posullivan@heritagerealty.com
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. ANNOUNCES
EXERCISE OF OVER-ALLOTMENT OPTION
BOSTON, December 26, 2003 /PRNewswire-FirstCall/ Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced that Deutsche Bank Securities Inc., the underwriter for its recently completed equity offering, has exercised its over- _____________
HERITAGE PROPERTY INVESTMENT TRUST, – these securities may be obtained when available from Deutsche Banc Securities Inc., 60 Wall Street, 10th Floor, New York, New York, 10005.
ABOUT HERITAGE PROPERTY INVESTMENT TRUST, INC.
Heritage is a fully integrated, self-administered and self-managed REIT traded on the New York Stock Exchange under the symbol _____________
dt 175630
;
| Patrick OSullivan;
Claire Koeneman;
More... |
| Preview
Full Doc
 | 2003 |
Heritage Property Investment Trust, Inc. Raises Approximately $100 Million in Common Stock Offering
Heritage Property Investment Trust, Inc. Raises Approximately $100 Million in Common Stock Offering (5K)
Doc #267563: Click preview link for longer preview.
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. RAISES APPROXIMATELY $100 MILLION IN COMMON STOCK OFFERING
BOSTON, December 16, 2003 Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced that it has completed a public offering of 3,500,000 shares of common stock at $28.27 per share, after the underwriting discount. In addition, The Prudential Insurance Company of America, our second largest stockholder, and its affiliate, PIM Foreign Investments, Inc. are selling an additional 1,935,556 shares in this offering. The offering is being underwritten by Deutsche Bank Securities Inc. and is expected to close on December 19, 2003.
The Company and the selling stockholders have also granted Deutsche Bank Securities Inc. an over-allotment option to purchase an additional 815,333 shares of common stock.
The Companys largest stockholder, Net Realty Holding Trust, a subsidiary of The New England Teamsters and Trucking Industry Pension Fund, has agreed to purchase approximately 1,400,000 shares, or approximately 40% of the shares being offered, pursuant to a contractual right Heritage granted to Net Realty Holding Trust to permit it to maintain its ownership percentage in the Company. Net Realty Holding Trust will purchase the shares on the same terms and conditions as other purchasers.
267563
|
Deutsche Bank
As referenced in this Heritage Property Investment Trust, Inc. Raises Approximately $100 Million in Common Stock Offering:
Deutsche Bank Securities Inc – its affiliate, PIM Foreign Investments, Inc. are selling an additional 1,935,556 shares in this offering. The offering is being underwritten by Deutsche Bank Securities Inc . and is expected to close on December 19, 2003.
The Company and the selling stockholders have also granted Deutsche Bank Securities Inc. _____________
Deutsche Bank Securities Inc – by Deutsche Bank Securities Inc. and is expected to close on December 19, 2003.
The Company and the selling stockholders have also granted Deutsche Bank Securities Inc . an over-allotment option to purchase an additional 815,333 shares of common stock.
The Companys largest stockholder, Net Realty Holding Trust, _____________
dt 161598
;
Heritage
As referenced in this Heritage Property Investment Trust, Inc. Raises Approximately $100 Million in Common Stock Offering:
HERITAGE PROPERTY INVESTMENT TRUST, – President, Finance and Accounting
(Analyst Info)
(General Info)
(617) 247-2200
(312) 640-6745
(212) 445-8434
posullivan@heritagerealty.com
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. RAISES APPROXIMATELY $100
MILLION IN COMMON STOCK OFFERING
BOSTON, December 16, 2003 Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced _____________
Heritage Property Investment Trust, – posullivan@heritagerealty.com
FOR IMMEDIATE RELEASE
HERITAGE PROPERTY INVESTMENT TRUST, INC. RAISES APPROXIMATELY $100
MILLION IN COMMON STOCK OFFERING
BOSTON, December 16, 2003 Heritage Property Investment Trust, Inc. (NYSE: HTG) today announced that it has completed a public offering of 3,500,000 shares of common stock at $28. _____________
HERITAGE PROPERTY INVESTMENT TRUST, – these securities may be obtained when available from Deutsche Banc Securities Inc., 60 Wall Street, 10th Floor, New York, New York, 10005.
ABOUT HERITAGE PROPERTY INVESTMENT TRUST, INC.
Heritage is a fully integrated, self-administered and self-managed REIT traded on the New York Stock Exchange under the symbol _____________
dt 175631
;
| Patrick OSullivan;
Claire Koeneman;
More... |
| Full Doc
 | 2003 |
Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement
Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement (10K)
Doc #297201: This document is immediately available for purchase, but does not have a preview available for viewing.
Cephalon Inc
EX-99.1 4 a2121787zex-99_1.htm EXHIBIT 99.1 QuickLinks -- Click here to rapidly navigate through this document
Exhibit 99.1
News
Cephalon Contacts: Media: Robert W. Grupp 610-738-6402 rgrupp@cephalon.com
Investors: Chip Merritt 610-738-6376 cmerritt@Cephalon.com
CIMA Contact: James Hawley 952-947-8700 jim.hawley@cimalabs.com
For Immediate Release
Cephalon, Inc. and CIMA LABS INC. Sign Definitive Merger Agreement
Cash Merger for $34 Per . . .
297201
|
Deutsche Bank
As referenced in this Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement:
Deutsche Bank Securities Inc – and that Cephalon expects to maintain both of CIMA's Minnesota facilities.
JP Morgan acted as financial advisor to Cephalon in this transaction. Deutsche Bank Securities Inc . acted as financial advisor to CIMA.
Concurrent with the announcement of this definitive merger agreement, CIMA notified aaiPharma (Nasdaq: AAII) that it _____________
dt 257770
;
Cephalon
As referenced in this Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement:
Cephalon, Inc – Investors: Chip Merritt
610-738-6376
cmerritt@Cephalon.com
CIMA Contact:
James Hawley
952-947-8700
jim.hawley@cimalabs.com
For Immediate Release
Cephalon, Inc . and CIMA LABS INC. Sign Definitive Merger Agreement
Cash Merger for $34 Per CIMA Share;
Provides Cephalon with Drug Delivery Technologies;
Will _____________
Cephalon, Inc. – Cephalon with Drug Delivery Technologies;
Will Accelerate Development and Launch of New Pharmaceutical Products
West Chester, PA and Eden Prairie, MNNovember 3, 2003Cephalon, Inc. (Nasdaq: CEPH) and CIMA LABS INC. (Nasdaq: CIMA) announced today that they have signed a definitive merger agreement under which Cephalon will _____________
Cephalon, Inc – CIMA also offers Cephalon an opportunity to develop proprietary products using CIMA's innovative oral drug delivery technologies, including OraVescent . CIMA is
SOURCE: Cephalon, Inc .
145 Brandywine Parkway
West Chester, PA 19380-4245
(610) 344-0200
Fax (610) 344-0981
developing an OraVescent form of fentanyl, which, _____________
Cephalon, Inc – encouraged to log onto the investor relations section of www.cephalon.com and click on the webcast link to access the live call.
Cephalon, Inc .
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat _____________
Cephalon, Inc – investor relations section of www.cephalon.com and click on the webcast link to access the live call.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc . is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer _____________
dt 255985
;
|
Cephalon
As referenced in this Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement:
Cephalon, Inc – Investors: Chip Merritt
610-738-6376
cmerritt@Cephalon.com
CIMA Contact:
James Hawley
952-947-8700
jim.hawley@cimalabs.com
For Immediate Release
Cephalon, Inc . and CIMA LABS INC. Sign Definitive Merger Agreement
Cash Merger for $34 Per CIMA Share;
Provides Cephalon with Drug Delivery Technologies;
Will _____________
Cephalon, Inc. – Cephalon with Drug Delivery Technologies;
Will Accelerate Development and Launch of New Pharmaceutical Products
West Chester, PA and Eden Prairie, MNNovember 3, 2003Cephalon, Inc. (Nasdaq: CEPH) and CIMA LABS INC. (Nasdaq: CIMA) announced today that they have signed a definitive merger agreement under which Cephalon will _____________
Cephalon, Inc – CIMA also offers Cephalon an opportunity to develop proprietary products using CIMA's innovative oral drug delivery technologies, including OraVescent . CIMA is
SOURCE: Cephalon, Inc .
145 Brandywine Parkway
West Chester, PA 19380-4245
(610) 344-0200
Fax (610) 344-0981
developing an OraVescent form of fentanyl, which, _____________
Cephalon, Inc – encouraged to log onto the investor relations section of www.cephalon.com and click on the webcast link to access the live call.
Cephalon, Inc .
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat _____________
Cephalon, Inc – investor relations section of www.cephalon.com and click on the webcast link to access the live call.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc . is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer _____________
dt 255985
;
Cima Labs
As referenced in this Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement:
CIMA LABS – 610-738-6376
cmerritt@Cephalon.com
CIMA Contact:
James Hawley
952-947-8700
jim.hawley@cimalabs.com
For Immediate Release
Cephalon, Inc. and CIMA LABS INC. Sign Definitive Merger Agreement
Cash Merger for $34 Per CIMA Share;
Provides Cephalon with Drug Delivery Technologies;
Will Accelerate Development and Launch _____________
CIMA LABS – Technologies;
Will Accelerate Development and Launch of New Pharmaceutical Products
West Chester, PA and Eden Prairie, MNNovember 3, 2003Cephalon, Inc. (Nasdaq: CEPH) and CIMA LABS INC. (Nasdaq: CIMA) announced today that they have signed a definitive merger agreement under which Cephalon will acquire all the outstanding common shares _____________
CIMA LABS – Cephalon and full prescribing information on its U.S. products is available at www.cephalon.com or by calling 1-800-896-5855.
CIMA LABS INC.
CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies, OraSolv and DuraSolv. _____________
CIMA LABS – the transaction, the timing and success of integration efforts once the transaction is complete, its expectations or ability to realize commercial success with CIMA LABS INC., the impact of this transaction, if successful, on Cephalon's business, anticipated scientific progress on its research programs, development of potential pharmaceutical _____________
dt 256298
;
Cima Labs
As referenced in this Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement:
CIMA LABS – 610-738-6376
cmerritt@Cephalon.com
CIMA Contact:
James Hawley
952-947-8700
jim.hawley@cimalabs.com
For Immediate Release
Cephalon, Inc. and CIMA LABS INC. Sign Definitive Merger Agreement
Cash Merger for $34 Per CIMA Share;
Provides Cephalon with Drug Delivery Technologies;
Will Accelerate Development and Launch _____________
CIMA LABS – Technologies;
Will Accelerate Development and Launch of New Pharmaceutical Products
West Chester, PA and Eden Prairie, MNNovember 3, 2003Cephalon, Inc. (Nasdaq: CEPH) and CIMA LABS INC. (Nasdaq: CIMA) announced today that they have signed a definitive merger agreement under which Cephalon will acquire all the outstanding common shares _____________
CIMA LABS – Cephalon and full prescribing information on its U.S. products is available at www.cephalon.com or by calling 1-800-896-5855.
CIMA LABS INC.
CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies, OraSolv and DuraSolv. _____________
CIMA LABS – the transaction, the timing and success of integration efforts once the transaction is complete, its expectations or ability to realize commercial success with CIMA LABS INC., the impact of this transaction, if successful, on Cephalon's business, anticipated scientific progress on its research programs, development of potential pharmaceutical _____________
dt 256298
|
| Preview
Full Doc
 | 2004 |
Omega Healthcare Announces Closing of Common Stock Offering
Omega Healthcare Announces Closing of Common Stock Offering (3K)
Doc #262346: Click preview link for longer preview.
 Omega Healthcare Investors Inc
EX-99.1 3 a2130848zex-99_1.htm EXHIBIT 99.1 QuickLinks -- Click here to rapidly navigate through this document
Exhibit 99.1
FOR IMMEDIATE RELEASE
OMEGA HEALTHCARE ANNOUNCES CLOSING OF COMMON STOCK OFFERING
Timonium, Maryland (March 8, 2004). Omega Healthcare Investors, Inc. (NYSE:OHI) today announced the closing of the underwritten public offering of 18,118,246 shares of Omega common stock at $9.85 per share. All of the shares sold in the offering were offered by Explorer Holdings, L.P. ("Explorer"). As a result of the offering, Explorer no longer owns any of Omega's common stock. Omega did not receive any proceeds from the sale of the shares sold by Explorer.
Omega has granted the underwriters a 30-day option to buy up to 2,717,736 additional shares of Omega common stock at a price of $9.85 per share, less underwriting discounts, to cover over-allotments, if any, in connection with the offering. Omega will receive all of the net proceeds from the offering of the additional shares of Omega common stock if the over-allotment option is exercised.
The joint book running managers for the common stock offering are UBS Investment Bank and Deutsche Bank Securities. The co-lead manager is Banc of America Securities LLC.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state. Copies of the prospectus supplement and related prospectuses may be obtained from the offices of UBS Investment Bank, ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001.
Omega Healthcare is a Real Estate Investment Trust investing in and providing financing to the long-term care industry. At December 31, 2003, Omega Healthcare owned or held mortgages on 211 skilled nursing and assisted living facilities with approximately 21,500 beds located in 28 states and operated by 39 third-party healthcare operating companies.
This announcement includes forward-looking statements. All forward-looking statements included herein are based on information available to the Company on the date hereof. Actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) conditions in the capital markets that may affect the ability to complete the offering described, and satisfaction of customary closing conditions; (ii) uncertainties relating to the business operations of the operators of the Company's properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (iii) regulatory and other changes in the healthcare sector, including without limitation, changes in Medicare reimbursement; (iv) changes in the financial position of the Company's operators; and (v) other factors identified in Omega's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Such statements only speak as of the date hereof and the Company assumes no obligation to update such forward-looking statements.
CONTACT: Omega Healthcare Investors, Inc. Bob Stephenson, CFO, 410-427-1700
********
QuickLinks
OMEGA HEALTHCARE ANNOUNCES CLOSING OF COMMON STOCK OFFERING
262346
|
Deutsche Bank
As referenced in this Omega Healthcare Announces Closing of Common Stock Offering:
Deutsche Bank Securities Inc – and related prospectuses may be obtained from the offices of UBS Investment Bank, ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc ., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New _____________
dt 161556
;
Omega Healthcare
As referenced in this Omega Healthcare Announces Closing of Common Stock Offering:
Omega Healthcare Investors, – navigate through this document
Exhibit 99.1
FOR IMMEDIATE RELEASE
OMEGA HEALTHCARE ANNOUNCES CLOSING
OF COMMON STOCK OFFERING
Timonium, Maryland (March 8, 2004). Omega Healthcare Investors, Inc. (NYSE:OHI) today announced the closing of the underwritten public offering of 18,118,246 shares of Omega common stock at $ _____________
Omega Healthcare Investors, – otherwise. Such statements only speak as of the date hereof and the Company assumes no obligation to update such forward-looking statements.
CONTACT: Omega Healthcare Investors, Inc.
Bob Stephenson, CFO, 410-427-1700
********
QuickLinks
OMEGA HEALTHCARE ANNOUNCES CLOSING OF COMMON STOCK OFFERING
_____________
dt 144728
;
|
BofA Securities
As referenced in this Omega Healthcare Announces Closing of Common Stock Offering:
Banc of America Securities LLC – The joint book running managers for the common stock offering are UBS Investment Bank and Deutsche Bank Securities. The co-lead manager is Banc of America Securities LLC .
This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any _____________
Banc of America Securities LLC – ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC , Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001.
Omega Healthcare is a Real Estate Investment Trust investing in and _____________
dt 139840
|
| Preview
Full Doc
 | 2004 |
Omega Healthcare Announces Proposed Secondary Offering by Explorer Holdings and Plans for Notes Offering and Refinancing of Credit Facility
Omega Healthcare Announces Proposed Secondary Offering by Explorer Holdings and Plans for Notes Offering and Refinancing of Credit Facility (5K)
Doc #262352: Click preview link for longer preview.
 Omega Healthcare Investors Inc
EX-99.1 4 a2129332zex-99_1.htm EX 99.1 QuickLinks -- Click here to rapidly navigate through this document
Exhibit 99.1
FOR IMMEDIATE RELEASE
OMEGA HEALTHCARE ANNOUNCES PROPOSED SECONDARY OFFERING BY EXPLORER HOLDINGS and Plans for Notes Offering and Refinancing of Credit Facility
Timonium, Maryland (February 23, 2004). Omega Healthcare Investors, Inc. (NYSE: OHI) today announced that Explorer Holdings, L.P. ("Explorer"), its largest stockholder, proposes to offer 18,118,246 shares of common stock of Omega in an underwritten public offering.
Omega plans to grant the underwriters a 30-day option to buy up to 2,717,736 additional shares of Omega common stock to cover over-allotments, if any, in connection with the proposed offering. Omega will not receive any proceeds from the sale of the shares sold by Explorer, and will only receive proceeds from the offering if the over-allotment option is exercised.
The joint book running managers for the common stock offering are UBS Investment Bank and Deutsche Bank Securities. The co-lead manager is Banc of America Securities LLC.
A registration statement relating to the securities offered by Explorer has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state. Copies of the preliminary prospectus supplement and related prospectuses may be obtained from the offices of UBS Investment Bank, ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001.
Omega also announced today its intention to offer approximately $200 million in principal amount of unsecured notes in a private placement contemplating resales in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omega anticipates using the proceeds of the notes offering together with the proceeds from a planned approximately $125 million new senior credit facility, to repay borrowings under Omega's existing senior secured credit facility maturing in 2007, to redeem shares of Omega's 9.25% Series A preferred stock, and for general corporate purposes. The proposed refinancing and notes offering, if completed, would replace Omega's existing $225 million senior secured credit facility and $50 million acquisition credit facility, which would be terminated. Omega cannot provide assurance that the refinancing of its existing credit facilities or the proposed note offering will be completed, or as to what the terms of the replacement financing would be.
The notes have not been registered under the Securities Act. Accordingly, the notes may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from registration under the Securities Act.
Omega Healthcare is a Real Estate Investment Trust investing in and providing financing to the long-term care industry. At December 31, 2003, Omega Healthcare owned or held mortgages on 211 skilled nursing and assisted living facilities with approximately 21,500 beds located in 28 states and operated by 39 third-party healthcare operating companies.
This announcement includes forward-looking statements. All forward-looking statements included herein are based on information available to the Company on the date hereof. Actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among
other things: (i) conditions in the capital markets that may affect the availability and cost of capital, and to complete the offerings described; (ii) uncertainties relating to the business operations of the operators of the Company's properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (iii) regulatory and other changes in the healthcare sector, including without limitation, changes in Medicare reimbursement; (iv) changes in the financial position of the Company's operators; and (v) other factors identified in Omega's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Such statements only speak as of the date hereof and the Company assumes no obligation to update such forward-looking statements.
CONTACT: Omega Healthcare Investors, Inc. Bob Stephenson, CFO, 410-427-1700
********
QuickLinks
262352
|
Deutsche Bank
As referenced in this Omega Healthcare Announces Proposed Secondary Offering by Explorer Holdings and Plans for Notes Offering and Refinancing of Credit Facility:
Deutsche Bank Securities Inc – and related prospectuses may be obtained from the offices of UBS Investment Bank, ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc ., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New _____________
dt 161559
;
Omega Healthcare
As referenced in this Omega Healthcare Announces Proposed Secondary Offering by Explorer Holdings and Plans for Notes Offering and Refinancing of Credit Facility:
Omega Healthcare Investors, – HEALTHCARE ANNOUNCES PROPOSED
SECONDARY OFFERING BY EXPLORER HOLDINGS
and
Plans for Notes Offering and Refinancing of Credit Facility
Timonium, Maryland (February 23, 2004). Omega Healthcare Investors, Inc. (NYSE: OHI) today announced that Explorer Holdings, L.P. ("Explorer"), its largest stockholder, proposes to offer 18,118,246 shares of _____________
Omega Healthcare Investors, – otherwise. Such statements only speak as of the date hereof and the Company assumes no obligation to update such forward-looking statements.
CONTACT: Omega Healthcare Investors, Inc.
Bob Stephenson, CFO, 410-427-1700
********
QuickLinks
Exhibit 99.1
_____________
dt 144734
;
|
BofA Securities
As referenced in this Omega Healthcare Announces Proposed Secondary Offering by Explorer Holdings and Plans for Notes Offering and Refinancing of Credit Facility:
Banc of America Securities LLC – The joint book running managers for the common stock offering are UBS Investment Bank and Deutsche Bank Securities. The co-lead manager is Banc of America Securities LLC .
A registration statement relating to the securities offered by Explorer has been filed with the Securities and Exchange Commission but has not _____________
Banc of America Securities LLC – ECMG Syndicate, 299 Park Avenue, New York, NY 10171; from Deutsche Bank Securities Inc., 60 Wall Street, New York, NY 10021; or from Banc of America Securities LLC , Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001.
Omega also announced today its intention to offer approximately $200 million _____________
dt 139844
|
| Preview
Full Doc
 | 2004 |
Intrabiotics Prices Common Stock Public Offering
Intrabiotics Prices Common Stock Public Offering (3K)
Doc #278035: Click preview link for longer preview.
{DOCUMENT} {TYPE}EX-99.1 {SEQUENCE}2 {FILENAME}f98800exv99w1.txt {DESCRIPTION}EXHIBIT 99.1 {TEXT} {PAGE} EXHIBIT 99.1
[INTRABIOTICS LETTERHEAD]
CONTACT: FOR IMMEDIATE RELEASE -------- Joyce Bremer (investors) IntraBiotics Pharmaceuticals, Inc. (650) 526-6818
Ian McConnell (media) WeissCom Partners, Inc. (415) 362-5018
INTRABIOTICS PRICES COMMON STOCK PUBLIC OFFERING
PALO ALTO, CA, MAY 5, 2004 -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq:IBPI) today announced that it has priced an offering of 3,000,000 shares of its common stock at $13.00 per share for estimated net proceeds to IntraBiotics of approximately $36.1 million. The underwriters have a 30-day option to purchase up to 450,000 additional shares of common stock from the Company solely to cover over-allotments, if any. All of the shares are being offered by IntraBiotics.
The bookrunning manager for the offering is Deutsche Bank Securities Inc. Piper Jaffray & Co. is acting as co-lead manager and Lazard Freres & Co. LLC is the sole co-manager.
The shares of common stock may only be offered by means of a prospectus. Copies of the final prospectus can be obtained from the Prospectus Department of Deutsche Bank Securities Inc. (60 Wall Street, 4th Floor, New York, NY 10005), or from the offices of any of the other managers identified above.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
ABOUT INTRABIOTICS IntraBiotics Pharmaceuticals, Inc. is focused on the development of novel antimicrobial drugs designed to overcome many of the shortcomings of currently prescribed anti-infectives, including the growing problem of multi-drug resistance. IntraBiotics' product candidate, iseganan, is in clinical development for two indications. The Food and Drug Administration (FDA) has granted Fast Track designation for the development of iseganan for the prevention of ventilator-associated pneumonia, the most common infection occurring in hospital intensive care units. The Company is also developing iseganan as a potential treatment of lung infections associated with cystic fibrosis.
STATEMENTS IN THIS PRESS RELEASE CONTAIN "FORWARD-LOOKING" INFORMATION WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934. THESE STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING INVESTOR RESPONSE TO THE OFFERING, THE TRADING PRICES FOR THE COMMON STOCK OF INTRABIOTICS, OTHER CONDITIONS IN THE FINANCIAL MARKETS, AND CUSTOMARY CLOSING CONDITIONS RELATED TO THE PUBLIC OFFERING. PLEASE SEE INTRABIOTICS' FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION FOR A DISCUSSION OF OTHER FACTORS THAT MAY AFFECT FORWARD-LOOKING INFORMATION.
# # #
{/TEXT} {/DOCUMENT}
278035
|
Deutsche Bank
As referenced in this Intrabiotics Prices Common Stock Public Offering:
Deutsche Bank Securities Inc – solely to cover
over-allotments, if any. All of the shares are being offered by IntraBiotics.
The bookrunning manager for the offering is Deutsche Bank Securities Inc . Piper
Jaffray & Co. is acting as co-lead manager and Lazard Freres & Co. LLC is the
sole co-manager.
The shares of _____________
Deutsche Bank Securities Inc – stock may only be offered by means of a prospectus. Copies
of the final prospectus can be obtained from the Prospectus Department of
Deutsche Bank Securities Inc . (60 Wall Street, 4th Floor, New York, NY 10005),
or from the offices of any of the other managers identified above.
This _____________
dt 198921
;
|
IntraBiotics
As referenced in this Intrabiotics Prices Common Stock Public Offering:
IntraBiotics Pharmaceuticals, – SEQUENCE}2
{FILENAME}f98800exv99w1.txt
{DESCRIPTION}EXHIBIT 99.1
{TEXT}
{PAGE}
EXHIBIT 99.1
[INTRABIOTICS LETTERHEAD]
CONTACT: FOR IMMEDIATE RELEASE
--------
Joyce Bremer (investors)
IntraBiotics Pharmaceuticals, Inc.
(650) 526-6818
Ian McConnell (media) WeissCom Partners, Inc.
(415) 362-5018
INTRABIOTICS PRICES COMMON STOCK PUBLIC OFFERING
PALO ALTO, CA, _____________
IntraBiotics Pharmaceuticals, – 526-6818
Ian McConnell (media) WeissCom Partners, Inc.
(415) 362-5018
INTRABIOTICS PRICES COMMON STOCK PUBLIC OFFERING
PALO ALTO, CA, MAY 5, 2004 -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq:IBPI)
today announced that it has priced an offering of 3,000,000 shares of its common
stock at $13. _____________
IntraBiotics Pharmaceuticals, – such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state.
ABOUT INTRABIOTICS
IntraBiotics Pharmaceuticals, Inc. is focused on the development of novel
antimicrobial drugs designed to overcome many of the shortcomings of currently
prescribed anti-infectives, _____________
dt 211985
|
| Preview
Full Doc
 | 2004 | |
Deutsche Bank
As referenced in this Intrabiotics Files Registration Statement for Public Offering:
Deutsche Bank Securities Inc – 000 shares to cover any over-allotments. All of the shares are being offered by IntraBiotics.
The bookrunning manager for the offering is Deutsche Bank Securities Inc . Piper Jaffray & Co. and Lazard Frres & Co. LLC will also act as managers in the offering.
The preliminary prospectus is not yet _____________
Deutsche Bank Securities Inc – as managers in the offering.
The preliminary prospectus is not yet available. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc ., 60 Wall Street, 4th Floor, New York, NY 10005, or from the offices of any of the managing underwriters identified above.
A _____________
dt 198925
;
|
IntraBiotics
As referenced in this Intrabiotics Files Registration Statement for Public Offering:
IntraBiotics Pharmaceuticals, –
exv99w1
EX-99.1 3 f98174exv99w1.htm EXHIBIT 99.1
Exhibit 99.1
CONTACT:
Joyce Bremer (investors)
IntraBiotics Pharmaceuticals, Inc.
(650) 526-6818
FOR IMMEDIATE RELEASE
Ian McConnell (media)
WeissCom Partners, Inc.
(415) 362-5018
INTRABIOTICS FILES REGISTRATION STATEMENT FOR PUBLIC _____________
IntraBiotics Pharmaceuticals, – RELEASE
Ian McConnell (media)
WeissCom Partners, Inc.
(415) 362-5018
INTRABIOTICS FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING
PALO ALTO, CA, April 14, 2004 IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI) today announced the filing with the Securities and Exchange Commission of a registration statement for a proposed public offering _____________
IntraBiotics Pharmaceuticals, – such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About IntraBiotics
IntraBiotics Pharmaceuticals, Inc. is focused on the development of novel biopharmaceutical products for the management of serious infections, including those involving multi-drug resistant _____________
dt 211989
|
| Preview
Full Doc
 | 2005 |
Agreement and Deed of Mortgage
Agreement and Deed of Mortgage (35K)
Doc #1367330: Click preview link for longer preview.
1 November 2004
AGREEMENT AND DEED OF MORTGAGE
IJS/6001933/231361hpe
AND PLEDGE
01-11-2004
6(231361)
Today, the second of November
two thousand and four, appeared before me,
Paul Hubertus Nicolaas Quist, civil-law notary, residing in Amsterdam:
1. Monique Maria Hemmers, care of Stibbe, 1077 ZZ Amsterdam, Strawinskylaan 2001, born in Eindhoven on the twentieth day of June nineteen hundred and seventy-one, in the present matter acting as holder of a . . .
1367330
|
Deutsche Bank
As referenced in this Agreement and Deed of Mortgage:
Deutsche Bank Securities Inc – V., the Mortgagor, the Lenders party thereto, the Collateral Agent (as Administrative Agent and as Collateral Agent for the Secured Parties), ABN AMRO Bank N.V. (as Syndication Agent) and Deutsche Bank Securities Inc . and ABN AMRO Incorporated (as Joint Lead Arrangers) entered into a five hundred thirty-five million American Dollars (USD 535,000,000) Credit Agreement (the Credit Agreement);
B. on _____________
dt 1377117
;
ABN AMRO Bank
As referenced in this Agreement and Deed of Mortgage:
ABN AMRO Bank N.V. – thousand and four, amongst others, New Skies Holding B.V., the Mortgagor, the Lenders party thereto, the Collateral Agent (as Administrative Agent and as Collateral Agent for the Secured Parties), ABN AMRO Bank N.V. (as Syndication Agent) and Deutsche Bank Securities Inc. and ABN AMRO Incorporated (as Joint Lead Arrangers) entered into a five hundred thirty-five million American Dollars (USD 535,000, _____________
dt 1471225
;
|
ABN AMRO Bank
As referenced in this Agreement and Deed of Mortgage:
ABN AMRO Bank N.V. – thousand and four, amongst others, New Skies Holding B.V., the Mortgagor, the Lenders party thereto, the Collateral Agent (as Administrative Agent and as Collateral Agent for the Secured Parties), ABN AMRO Bank N.V. (as Syndication Agent) and Deutsche Bank Securities Inc. and ABN AMRO Incorporated (as Joint Lead Arrangers) entered into a five hundred thirty-five million American Dollars (USD 535,000, _____________
dt 1471225
|
| Preview
Full Doc
 | 2003 |
Agreement of Lease
Agreement of Lease (165K)
Doc #990763: Click preview link for longer preview.
|
Deutsche Bank
As referenced in this Agreement of Lease:
Deutsche Bank Securities, Inc – Landlord
acknowledges that Tenant is currently occupying the Premises pursuant to that
certain Sublease dated November 21, 2002 (the DB Sublease) by and between
Tenant, as subtenant, and Deutsche Bank Securities, Inc . (DB), as
sublandlord, for a term that expires on May 31, 2004, and it is the intention
of the parties hereunder that this Lease will commence at _____________
dt 1376439
;
COPT
As referenced in this Agreement of Lease:
Corporate Office Properties Trust
– 160; ATRIUM BUILDING, LLC
c/o Corporate Office Properties Trust
Suite 400, 8815 Centre Park Drive
Columbia, Maryland 21045
Deutsche Bank Trust Company
Americas f/k/a Bankers Trust Company
200 Crescent Court, Suite
550
Dallas, Texas 75201
_____________
dt 1401544
;
TESSCO
As referenced in this Agreement of Lease:
TESSCO TECHNOLOGIES, INC. – TESSCO Technologies Inc
EX-10.1
3
a03-5185_1ex10d1.htm
EX-10.1
Exhibit
10.1
AGREEMENT OF LEASE
by and between
ATRIUM BUILDING, LLC
and
TESSCO TECHNOLOGIES, INC.
(375 WEST PADONIA ROAD, SUITE 100)
AGREEMENT OF LEASE
ATRIUM BUILDING, LLC
TESSCO TECHNOLOGIES, INC.
TABLE OF CONTENTS
1.
Definitions and
Attachments
2.
Demise
3.
Commencement Date and
Term
_____________
TESSCO TECHNOLOGIES, INC. – 10.1
Exhibit
10.1
AGREEMENT OF LEASE
by and between
ATRIUM BUILDING, LLC
and
TESSCO TECHNOLOGIES, INC.
(375 WEST PADONIA ROAD, SUITE 100)
AGREEMENT OF LEASE
ATRIUM BUILDING, LLC
TESSCO TECHNOLOGIES, INC.
TABLE OF CONTENTS
1.
Definitions and
Attachments
2.
Demise
3.
Commencement Date and
Term
4.
Intentionally
Deleted
5.
Use
6.
Rent
7.
Requirements of
Applicable Law
8.
Certificate of
_____________
TESSCO TECHNOLOGIES, INC. – LEASE
THIS AGREEMENT OF LEASE (this Lease)
made this
day of
,
2003 (the Effective Date), by
and between ATRIUM BUILDING, LLC (the
Landlord) and TESSCO TECHNOLOGIES, INC. (the Tenant), witnesseth that the parties
hereby agree as follows:
W
I T N E S S E T H:
THAT FOR AND IN CONSIDERATION of the _____________
TESSCO TECHNOLOGIES, INC. – Lease as of the day and year first above written.
WITNESS OR ATTEST:
LANDLORD:
ATRIUM BUILDING, LLC
By:
(SEAL)
Roger A. Waesche, Jr.
Senior Vice President
WITNESS OR ATTEST:
TENANT:
TESSCO TECHNOLOGIES, INC.
By:
(SEAL)
Name:
Title:
STATE OF
MARYLAND, ,
TO WIT:
I HEREBY CERTIFY, that on
this day of
,
2003, before me, the undersigned Notary Public of the State, personally
_____________
TESSCO TECHNOLOGIES,
INC. – the State, personally
appeared
,
known to me (or satisfactorily proven) to be the person whose name is
subscribed to the within instrument, and acknowledged himself/herself to be the
of TESSCO TECHNOLOGIES,
INC. a
corporation, and that he/she, as such
,
being authorized so to do, executed the foregoing instrument on behalf of the
corporation by himself/herself as such
.
WITNESS my _____________
dt 1453613
;
|
TESSCO
As referenced in this Agreement of Lease:
TESSCO TECHNOLOGIES, INC. – TESSCO Technologies Inc
EX-10.1
3
a03-5185_1ex10d1.htm
EX-10.1
Exhibit
10.1
AGREEMENT OF LEASE
by and between
ATRIUM BUILDING, LLC
and
TESSCO TECHNOLOGIES, INC.
(375 WEST PADONIA ROAD, SUITE 100)
AGREEMENT OF LEASE
ATRIUM BUILDING, LLC
TESSCO TECHNOLOGIES, INC.
TABLE OF CONTENTS
1.
Definitions and
Attachments
2.
Demise
3.
Commencement Date and
Term
_____________
TESSCO TECHNOLOGIES, INC. – 10.1
Exhibit
10.1
AGREEMENT OF LEASE
by and between
ATRIUM BUILDING, LLC
and
TESSCO TECHNOLOGIES, INC.
(375 WEST PADONIA ROAD, SUITE 100)
AGREEMENT OF LEASE
ATRIUM BUILDING, LLC
TESSCO TECHNOLOGIES, INC.
TABLE OF CONTENTS
1.
Definitions and
Attachments
2.
Demise
3.
Commencement Date and
Term
4.
Intentionally
Deleted
5.
Use
6.
Rent
7.
Requirements of
Applicable Law
8.
Certificate of
_____________
TESSCO TECHNOLOGIES, INC. – LEASE
THIS AGREEMENT OF LEASE (this Lease)
made this
day of
,
2003 (the Effective Date), by
and between ATRIUM BUILDING, LLC (the
Landlord) and TESSCO TECHNOLOGIES, INC. (the Tenant), witnesseth that the parties
hereby agree as follows:
W
I T N E S S E T H:
THAT FOR AND IN CONSIDERATION of the _____________
TESSCO TECHNOLOGIES, INC. – Lease as of the day and year first above written.
WITNESS OR ATTEST:
LANDLORD:
ATRIUM BUILDING, LLC
By:
(SEAL)
Roger A. Waesche, Jr.
Senior Vice President
WITNESS OR ATTEST:
TENANT:
TESSCO TECHNOLOGIES, INC.
By:
(SEAL)
Name:
Title:
STATE OF
MARYLAND, ,
TO WIT:
I HEREBY CERTIFY, that on
this day of
,
2003, before me, the undersigned Notary Public of the State, personally
_____________
TESSCO TECHNOLOGIES,
INC. – the State, personally
appeared
,
known to me (or satisfactorily proven) to be the person whose name is
subscribed to the within instrument, and acknowledged himself/herself to be the
of TESSCO TECHNOLOGIES,
INC. a
corporation, and that he/she, as such
,
being authorized so to do, executed the foregoing instrument on behalf of the
corporation by himself/herself as such
.
WITNESS my _____________
dt 1453614
;
DB Trust
As referenced in this Agreement of Lease:
Deutsche Bank Trust Co – 160; ATRIUM BUILDING, LLC
c/o Corporate Office Properties Trust
Suite 400, 8815 Centre Park Drive
Columbia, Maryland 21045
Deutsche Bank Trust Co mpany
Americas f/k/a Bankers Trust Company
200 Crescent Court, Suite
550
Dallas, Texas 75201
Re: _____________
DEUTSCHE
BANK TRUST CO – or late |